Latch (LTCH) Competitors $0.20 -0.01 (-4.88%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends LTCH vs. TOI, AE, NHTC, RAVE, GDC, HYFM, BANL, SAG, FXLV, and UGROShould you be buying Latch stock or one of its competitors? The main competitors of Latch include Oncology Institute (TOI), Adams Resources & Energy (AE), Natural Health Trends (NHTC), Rave Restaurant Group (RAVE), GD Culture Group (GDC), Hydrofarm Holdings Group (HYFM), CBL International (BANL), SAG (SAG), F45 Training (FXLV), and urban-gro (UGRO). Latch vs. Oncology Institute Adams Resources & Energy Natural Health Trends Rave Restaurant Group GD Culture Group Hydrofarm Holdings Group CBL International SAG F45 Training urban-gro Oncology Institute (NASDAQ:TOI) and Latch (NASDAQ:LTCH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment. Which has more risk and volatility, TOI or LTCH? Oncology Institute has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Latch has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Do analysts recommend TOI or LTCH? Oncology Institute currently has a consensus price target of $2.50, indicating a potential upside of 1,523.38%. Given Oncology Institute's stronger consensus rating and higher possible upside, equities research analysts clearly believe Oncology Institute is more favorable than Latch.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncology Institute 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Latch 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in TOI or LTCH? 36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 0.4% of Latch shares are owned by institutional investors. 9.5% of Oncology Institute shares are owned by company insiders. Comparatively, 27.5% of Latch shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is TOI or LTCH more profitable? Latch has a net margin of 0.00% compared to Oncology Institute's net margin of -17.63%. Latch's return on equity of 0.00% beat Oncology Institute's return on equity.Company Net Margins Return on Equity Return on Assets Oncology Institute-17.63% -186.83% -34.58% Latch N/A N/A N/A Does the MarketBeat Community prefer TOI or LTCH? Latch received 5 more outperform votes than Oncology Institute when rated by MarketBeat users. However, 66.67% of users gave Oncology Institute an outperform vote while only 27.27% of users gave Latch an outperform vote. CompanyUnderperformOutperformOncology InstituteOutperform Votes466.67% Underperform Votes233.33% LatchOutperform Votes927.27% Underperform Votes2472.73% Does the media favor TOI or LTCH? In the previous week, Oncology Institute had 1 more articles in the media than Latch. MarketBeat recorded 2 mentions for Oncology Institute and 1 mentions for Latch. Latch's average media sentiment score of 0.00 beat Oncology Institute's score of -0.14 indicating that Latch is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncology Institute 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Latch 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, TOI or LTCH? Oncology Institute has higher revenue and earnings than Latch. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncology Institute$324.24M0.04-$83.07M-$0.78-0.20Latch$41.36M0.68-$166.32MN/AN/A SummaryOncology Institute and Latch tied by winning 8 of the 16 factors compared between the two stocks. Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get Latch News Delivered to You Automatically Sign up to receive the latest news and ratings for LTCH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTCH vs. The Competition Export to ExcelMetricLatchHardware IndustryAuto SectorNASDAQ ExchangeMarket Cap$30.16M$2.01B$18.11B$8.84BDividend YieldN/AN/A3.27%4.09%P/E RatioN/A12.2615.1417.58Price / Sales0.680.6513.39158.43Price / CashN/A11.4911.8536.33Price / BookN/A1.392.366.50Net Income-$166.32M$21.84M$1.53B$226.22M7 Day Performance-76.77%-35.61%0.28%3.76%1 Month Performance-56.64%-11.57%-2.73%4.63%1 Year Performance-74.99%-4.03%-3.36%29.20% Latch Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTCHLatchN/A$0.20-4.9%N/A-75.0%$30.16M$41.36M0.00420TOIOncology Institute2.2827 of 5 stars$0.16+14.8%$2.50+1,512.9%-92.3%$11.70M$324.24M-0.20660Gap UpHigh Trading VolumeAEAdams Resources & Energy0.323 of 5 stars$37.20+0.1%$38.00+2.2%+29.2%$95.98M$2.75B-11.77710Analyst ForecastNHTCNatural Health Trends1.3222 of 5 stars$5.60+2.2%N/A+5.0%$64.46M$43.92M78.86140Analyst ForecastPositive NewsGap UpRAVERave Restaurant Group0.7472 of 5 stars$2.85-0.7%N/A+18.4%$42.22M$12.11M15.8221Analyst ForecastGDCGD Culture Group0.3822 of 5 stars$2.74+5.8%N/A-29.3%$29.82M$25.03M0.0060HYFMHydrofarm Holdings Group1.9388 of 5 stars$0.64+4.9%$0.70+9.5%-19.7%$29.48M$226.58M-0.45840News CoverageGap DownBANLCBL InternationalN/A$1.00-1.0%N/A-44.7%$27.50M$435.90M0.0035Gap DownSAGSAGN/A$2.67-2.2%N/AN/A$26.38MN/A0.00N/AFXLVF45 TrainingN/A$0.25-24.2%N/A+27.5%$24.73M$104.42M0.00160Gap DownUGROurban-gro2.2084 of 5 stars$1.64+3.8%$3.25+98.2%+33.9%$20.21M$71.54M-1.20100Gap Down Related Companies and Tools Related Companies Oncology Institute Alternatives Adams Resources & Energy Alternatives Natural Health Trends Alternatives Rave Restaurant Group Alternatives GD Culture Group Alternatives Hydrofarm Holdings Group Alternatives CBL International Alternatives SAG Alternatives F45 Training Alternatives urban-gro Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LTCH) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Latch, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Latch With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
